European bank to lend €16m to Petrovax

Published: 17-Jun-2011
Finance Pharmaceutical

To help Russian pharmaceutical firm commercialise immunology drugs


The European Bank for Reconstruction & Development (EBRD) is considering lending Russian pharmaceutical company NOP Petrovax Pharm up to €15.8m to help commercialise three new medicines to fight immunology and viral diseases.

Rusnano (the Russian Corporation of Nanotechnologies) is considering participating in the project.

Petrovax focuses on the development of generic drugs and vaccines.

See more

You may also like

Finance

Berry Global invests to increase production capacity for healthcare products

Read more
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  3. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
  4. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  5. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Finance

Berry Global invests to increase production capacity for healthcare products

Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Research & Development

SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials

Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Research & Development

SeaBeLife awarded over €1.5 million in i-Nov innovation competition

Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Subscribe now